CLINICAL RESEARCH: HYPERTROPHIC CARDIOMYOPATHY
Relevance of Coronary Microvascular Flow Impairment to Long-Term Remodeling and Systolic Dysfunction in Hypertrophic Cardiomyopathy
Iacopo Olivotto, MD*,*,
Franco Cecchi, MD*,
Roberto Gistri, MD*,
Roberto Lorenzoni, MD ,
Giampaolo Chiriatti, MD ,
Francesca Girolami, BSc ,
Francesca Torricelli, BSc and
Paolo G. Camici, MD, FACC, FRCP||,¶
* Regional Referral Center for Myocardial Diseases, Florence, Italy
Cytogenetics, Azienda Ospedaliera Careggi, Florence, Italy
Cardiology Unit, Ospedale di Lucca, Lucca, Italy
Cardiology Unit, Ospedale di Pescia, Pescia, Italy
|| Consiglio Nazionale delle Ricerche, Institute of Clinical Physiology, Pisa, Italy
¶ Medical Research Council Clinical Sciences Centre, Hammersmith Hospital, Imperial College, London, United Kingdom
Manuscript received May 27, 2005;
revised manuscript received September 30, 2005,
accepted October 17, 2005.
* Reprint requests and correspondence: Dr. Iacopo Olivotto, Centro di Riferimento per le Cardiomiopatie, Cardiologia San Luca, Azienda Ospedaliera Universitaria Careggi, Viale Pieraccini 19, 50134 Firenze, Italy (Email: olivottoi{at}ao-careggi.toscana.it).
OBJECTIVES: This study sought to evaluate whether the entity of microvascular dysfunction, assessed by positron emission tomography (PET), predicts the long-term development of left ventricular (LV) remodeling and systolic dysfunction in hypertrophic cardiomyopathy (HCM).
BACKGROUND: A subgroup of patients with HCM developed LV dilation and systolic impairment. A causal role of coronary microvascular dysfunction has been suggested as the underlying pathophysiological mechanism.
METHODS: Fifty-one patients (New York Heart Association functional class I to II) were followed up for 8.1 ± 2.1 years after measurement of resting and dipyridamole (Dip) myocardial blood flow (MBF). Left ventricular systolic dysfunction was defined as an ejection fraction (LVEF) <50%.
RESULTS: The Dip-MBF was blunted in HCM patients compared with a group of healthy control patients (1.50 ± 0.69 ml/min/g vs. 2.71 ± 0.94 ml/min/g; p < 0.001). At final evaluation, 11 patients (22%) had an LVEF <50%; in most (n = 7), systolic dysfunction was associated with a significant increase in LV cavity dimensions (>5 mm) during follow-up. These 11 patients showed lower Dip-MBF than the 40 with preserved LV function (1.04 ± 0.38 ml/min/g vs. 1.63 ± 0.71 ml/min/g, respectively; p = 0.001); Dip-MBF was particularly blunted in five patients with clinical progression to severe heart failure symptoms or death (Dip-MBF 0.89 ± 0.15 ml/min/g). At multivariate analysis, the two independent predictors of systolic dysfunction were Dip-MBF in the lowest tertile (<1.1 ml/min/g; relative hazard, 7.5; p = 0.038) and an end-diastolic LV dimension in the highest tertile (>45 mm; relative hazard, 12.3; p = 0.031).
CONCLUSIONS: Severe microvascular dysfunction is a potent long-term predictor of adverse LV remodeling and systolic dysfunction in HCM. Our findings indicate microvascular dysfunction as a potential target for prevention of disease progression and heart failure in HCM.
|
Abbreviations and Acronyms
| | Dip = dipyridamole | | HCM = hypertrophic cardiomyopathy | | LV = left ventricle/ventricular | | MBF = myocardial blood flow | | NYHA = New York Heart Association | | PET = positron emission tomography |
|
This article has been cited by other articles:
|
|
|
|
 
C. O'Mahony, P. D. Lambiase, G. Quarta, M. Cardona, M. Calcagnino, K. Tsovolas, S. Al-Shaikh, S. M. Rahman, S. Arnous, S. Jones, et al.
The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy
Heart,
January 15, 2012;
98(2):
116 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Deshpande, M. Pakkal, B. Agrawal, and V. Raj
Cardiac magnetic resonance imaging of non-ischaemic cardiomyopathy
Postgrad. Med. J.,
January 1, 2012;
88(1035):
38 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, H. Rakowski, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
December 13, 2011;
58(25):
2703 - 2738.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, H. Rakowski, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons
J. Am. Coll. Cardiol.,
December 13, 2011;
58(25):
e212 - e260.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
December 13, 2011;
124(24):
e783 - e831.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Circulation,
December 13, 2011;
124(24):
2761 - 2796.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members:*, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J. Thorac. Cardiovasc. Surg.,
December 1, 2011;
142(6):
1303 - 1338.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members:*, B. J. Gersh, B. J. Maron, R. O. Bonow, J. A. Dearani, M. A. Fifer, M. S. Link, S. S. Naidu, R. A. Nishimura, S. R. Ommen, et al.
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
J. Thorac. Cardiovasc. Surg.,
December 1, 2011;
142(6):
e153 - e203.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Olivotto, F. Girolami, R. Sciagra, M. J. Ackerman, B. Sotgia, J. M. Bos, S. Nistri, A. Sgalambro, C. Grifoni, F. Torricelli, et al.
Microvascular Function Is Selectively Impaired in Patients With Hypertrophic Cardiomyopathy and Sarcomere Myofilament Gene Mutations
J. Am. Coll. Cardiol.,
August 16, 2011;
58(8):
839 - 848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Ziadi, R. A. deKemp, K. A. Williams, A. Guo, B. J. W. Chow, J. M. Renaud, T. D. Ruddy, N. Sarveswaran, R. E. Tee, and R. S. B. Beanlands
Impaired Myocardial Flow Reserve on Rubidium-82 Positron Emission Tomography Imaging Predicts Adverse Outcomes in Patients Assessed for Myocardial Ischemia
J. Am. Coll. Cardiol.,
August 9, 2011;
58(7):
740 - 748.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Maron, I. Olivotto, C. Harrigan, E. Appelbaum, C. M. Gibson, J. R. Lesser, T. S. Haas, J. E. Udelson, W. J. Manning, and B. J. Maron
Mitral Valve Abnormalities Identified by Cardiovascular Magnetic Resonance Represent a Primary Phenotypic Expression of Hypertrophic Cardiomyopathy
Circulation,
July 5, 2011;
124(1):
40 - 47.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Gewirtz
Cardiac PET: A Versatile, Quantitative Measurement Tool for Heart Failure Management
J. Am. Coll. Cardiol. Img.,
March 1, 2011;
4(3):
292 - 302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Girolami, C. Y. Ho, C. Semsarian, M. Baldi, M. L. Will, K. Baldini, F. Torricelli, L. Yeates, F. Cecchi, M. J. Ackerman, et al.
Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations
J. Am. Coll. Cardiol.,
April 6, 2010;
55(14):
1444 - 1453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mizuno, S. Fujimoto, Y. Saito, and S. Nakamura
Cardiac Raynaud's phenomenon induced by cold provocation as a predictor of long-term left ventricular dysfunction and remodelling in systemic sclerosis: 7-year follow-up study
Eur J Heart Fail,
March 1, 2010;
12(3):
268 - 275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Fischer-Rasokat, B. Assmus, F. H. Seeger, J. Honold, D. Leistner, S. Fichtlscherer, V. Schachinger, T. Tonn, H. Martin, S. Dimmeler, et al.
A Pilot Trial to Assess Potential Effects of Selective Intracoronary Bone Marrow-Derived Progenitor Cell Infusion in Patients With Nonischemic Dilated Cardiomyopathy: Final 1-Year Results of the Transplantation of Progenitor Cells and Functional Regeneration Enhancement Pilot Trial in Patients With Nonischemic Dilated Cardiomyopathy
Circ Heart Fail,
September 1, 2009;
2(5):
417 - 423.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Maron, I. Olivotto, B. J. Maron, S. K. Prasad, F. Cecchi, J. E. Udelson, and P. G. Camici
The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy
J. Am. Coll. Cardiol.,
August 25, 2009;
54(9):
866 - 875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Camici and O. E. Rimoldi
The Clinical Value of Myocardial Blood Flow Measurement
J. Nucl. Med.,
July 1, 2009;
50(7):
1076 - 1087.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rudolph, H. Abdel-Aty, S. Bohl, P. Boye, A. Zagrosek, R. Dietz, and J. Schulz-Menger
Noninvasive Detection of Fibrosis Applying Contrast-Enhanced Cardiac Magnetic Resonance in Different Forms of Left Ventricular Hypertrophy: Relation to Remodeling
J. Am. Coll. Cardiol.,
January 20, 2009;
53(3):
284 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ashrafian and H. Watkins
Exercise-induced ventricular dysfunction in hypertrophic cardiomyopathy: stunning by any other name?
Heart,
October 1, 2008;
94(10):
1251 - 1253.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Sotgia, R. Sciagra, I. Olivotto, G. Casolo, L. Rega, I. Betti, A. Pupi, P. G. Camici, and F. Cecchi
Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy
J. Nucl. Med.,
July 1, 2008;
49(7):
1090 - 1096.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Knaapen, T. Germans, P. G. Camici, O. E. Rimoldi, F. J. ten Cate, J. M. ten Berg, P. A. Dijkmans, R. Boellaard, W. G. van Dockum, M. J. W. Gotte, et al.
Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy
Am J Physiol Heart Circ Physiol,
February 1, 2008;
294(2):
H986 - H993.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. McLeod, S. R. Ommen, M. J. Ackerman, P. L. Weivoda, W. K. Shen, J. A. Dearani, H. V. Schaff, A. J. Tajik, and B. J. Gersh
Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy
Eur. Heart J.,
November 1, 2007;
28(21):
2583 - 2588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. I I Soliman, P. Knaapen, M. L Geleijnse, P. A Dijkmans, A. M Anwar, A. Nemes, M. Michels, W. B Vletter, A. A Lammertsma, and F. J ten Cate
Assessment of intravascular and extravascular mechanisms of myocardial perfusion abnormalities in obstructive hypertrophic cardiomyopathy by myocardial contrast echocardiography
Heart,
October 1, 2007;
93(10):
1204 - 1212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Cheung, D. A. Bluemke, R. Klein, A. R. Sharrett, F.M. A. Islam, M. F. Cotch, B. E.K. Klein, M. H. Criqui, and T. Y. Wong
Retinal Arteriolar Narrowing and Left Ventricular Remodeling: The Multi-Ethnic Study of Atherosclerosis
J. Am. Coll. Cardiol.,
July 3, 2007;
50(1):
48 - 55.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Petersen, M. Jerosch-Herold, L. E. Hudsmith, M. D. Robson, J. M. Francis, H. A. Doll, J. B. Selvanayagam, S. Neubauer, and H. Watkins
Evidence for Microvascular Dysfunction in Hypertrophic Cardiomyopathy: New Insights From Multiparametric Magnetic Resonance Imaging
Circulation,
May 8, 2007;
115(18):
2418 - 2425.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
